Related Experiment Video

Updated: Mar 26, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K

Biosimilars and cancer treatment of older patients

Stuart M Lichtman1, Thomas Reske2, Ira A Jacobs3

  • 1Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Journal of Geriatric Oncology
|February 10, 2016
PubMed

Insights

Biosimilar monoclonal antibodies offer expanded access to cancer biologics, especially for older patients. This overview aids oncologists in understanding their development, approval, and management strategies.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Biosimilar monoclonal antibodies (mAbs) are emerging as critical therapeutic options in oncology.
  • Global development aims to increase patient access to advanced biologic therapies for cancer treatment.

Discussion:

  • This supplement provides an overview of biosimilar mAb development, regulatory approval pathways, and key characteristics.
  • It aims to familiarize oncologists and healthcare providers with these novel biologic agents.
  • Challenges and management strategies for older cancer patients receiving biosimilar mAbs are discussed.

Key Insights:

  • Biosimilar mAbs represent a significant advancement in making biologic cancer therapies more accessible.
  • Understanding the regulatory landscape and product specifics is crucial for clinical adoption.
  • Geriatric oncology requires tailored approaches for effective biosimilar mAb utilization.

Outlook:

  • Increased familiarity with biosimilar mAbs will facilitate their integration into standard cancer care.
  • Further research into the long-term efficacy and safety in diverse patient populations, particularly the elderly, is warranted.
  • Biosimilars are expected to play a vital role in addressing the growing clinical demand for biologics in oncology.
Keywords:
AccessAssessmentBiologicBiosimilarCancerComorbidityOlder patientsTargeted therapymAb

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.4K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
348
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
345